Hormonal therapy for cancer

Tomlins, 2005, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science, 310, 644, 10.1126/science.1117679

Early Breast Cancer Trialists’ Collaborative Group (EBCTC G), 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0

Saadat, 2007, Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen, Cancer, 110, 31, 10.1002/cncr.22734

Kelly, 2010, Selective serotonin inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study, Br Med J, 340, c693, 10.1136/bmj.c693

Royal College of Physicians, the Bone and Tooth Society, the National Osteoporosis Society, 2002

Attard, 2011, New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway, Clin Cancer Res, 17, 1649, 10.1158/1078-0432.CCR-10-0567

de Bono, 2011, Treatment with abiraterone acetate improves overall survival among men with metastatic prostate cancer, New Eng J Med, 364, 1995, 10.1056/NEJMoa1014618

Hanks, 2003, Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02, J Clin Oncol, 21, 3972, 10.1200/JCO.2003.11.023

Klotz L, O’Callaghan CJ, Ding K, et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. Procs 2011 Genitourinary Cancer Symposium.